PTGDR2

Across TCGA pan-cancer cohorts, PTGDR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTGDR2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTGDR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGDR2 expression acts as an unfavorable survival marker.

LUAD, BLCA, and ESCA are the cancer types where PTGDR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	28	view →
BLCA	DFS	Median	All	0.132	0.626	.006	18	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	OS	Median	III,IV	0.196	0.632	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTGDR2–LUAD (OS)

Open the LUAD breakdown →